Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Treatment of High Risk or Recurrent Ovarian Cancer With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells (BATs), Low Dose IL-2, and GM-CSF (Phase I).

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02470559
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:59.866800+00:00
Published At
2016-02-17T00:00:00+00:00
Record Updated At
2016-02-17
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Malignant Ovarian Clear Cell Tumor", "Malignant Ovarian Serous Tumor", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2016-02-17"
protocolSection.identificationModule.nctId
"NCT02470559"
protocolSection.identificationModule.officialTitle
"Treatment of High Risk or Recurrent Ovarian Cancer With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells (BATs), Low Dose IL-2, and GM-CSF (Phase I)."
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Malignant Ovarian Clear Cell Tumor (protocolSection.conditionsModule.conditions)
  • Malignant Ovarian Serous Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIIA Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.